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A CALMODULIN-LIKE Ca2" RECEPTOR
IN THE Ca2" CHANNEL
J. DAVID JOHNSON
Department ofPhysiological Chemistry, The Ohio State University, College ofMedicine, Columbus,
Ohio 43210
The voltage-dependent Ca2" channel, or slow channel,
transports Ca2" across the cell membrane and is regulated
by intracellular [Ca2"] (1). It must, therefore, bind Ca2"
itself, and some domain or region of the Ca2"-channel
protein must be a Ca2"-binding protein. Calmodulin
(CDR) is perhaps the most universal Ca2"-dependent
regulatory protein and we have studied it as a model for the
Ca2" receptor in the Ca2" channel. We have reported that
some Ca2"-antagonist drugs (Ca2" channel blockers), said
to be specific for the Ca2" channel, bind to calmodulin (2).
We have also shown that calmodulin antagonists (CDR-
ANT) can act like Ca2k-antagonists (Ca-ANT) and block
the Ca2, channel (3). Recently, allosteric interactions
among Ca-ANT drug-binding sites on the Ca2, channel
have been reported (4, 5). The present study demonstrates
allosteric interactions among the Ca-ANT-binding sites of
calmodulin. This provides further, indirect, evidence of a
Ca2+-binding protein, similar to but probably distinct from
calmodulin, serving as a regulator of the Ca2, channel and
a receptor for Ca-ANT drugs. With this information we
propose a model of the Ca2, channel and the mechanism of
action of Ca-ANT.
RESULTS
Ca2' binding to calmodulin is known to produce large
structural changes including the exposure of 3-4 hydro-
phobic ligand-binding sites (7). The dihydropyridine Ca-
ANT, felodipine, binds one to two of these sites on CDR
with a Kd of 1-10lM (8). The fluorescence spectra of
felodipine (Fig. 1, inset) is not changed by the addition of
CDR. The addition of Ca2" (but not Mg2"), only in the
presence of CDR, produces a twofold fluorescence increase
(Fig. 1, inset, curve 2). This suggests that Ca2' binding to
Ca2+-specific sites on CDR exposes felodipine binding sites
and that felodipine binding can be monitored by this
fluorescence increase. Addition of the CDR-ANT,
R2457 1, or the Ca-ANT, diltiazem, to Ca2+-CDR-felodi-
pine can produce a further fluorescence increase (Fig. 1,
inset curve 3) only in the presence of both Ca2+ and CDR.
This suggests that these drugs do not interact with free
felodipine but bind to a Ca2+-CDR complex to increase
felodipine binding to CDR.
In the same concentration range where R24571 and
diltiazem bind to CDR (2), we find that they produce an
increase in CDR-felodipine fluorescence; at higher concen-
trations this fluorescence increase is reversed (6). Initially,
these drugs bind to sites on CDR other than the felodipine-
binding sites. Through an allosteric mechanism they
increase the number and/or affinity of felodipine-binding
sites, resulting in the observed fluorescence increase. At
higher concentrations presumably they can bind to the
felodipine-binding sites and competitively displace felodi-
pine, resulting in the observed fluorescence decrease.
A titration of felodipine with CDR is shown in Fig. 1.
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FIGURE 1 Effect of Ca2" antagonists and calmodulin antagonists on
felodipine binding to calmodulin. The percent of the total fluorescence
increase in felodipine as a function of added calmodulin is shown in the
presence of 2 MM R24571 (@ ), 500 AM diltiazem (A-A) and in the
absence of added drug (O E). The total fluorescence increases were
3.1-, 10.8-, and 2.2-fold, respectively. Each cuvette contained 5 x 10-7 M
felodipine in 10 mM MOPS, 90 mM KCI, 2 mM EGTA buffer with 2.9
mM CaC12 added, and was titrated with CDR in the presence or absence
of drug. Inset. Fluorescence spectra of 1 MM felodipine (curve 1) in above
buffer followed by successive additions of 2 MAM calmodulin (curve 1), 3
mM CaCJ2 (curve 2), and 2MM R24571 (curve 3).
Half-maximal binding occurs at 8.5 ,uM (as estimated
from this fluorescence increase), in good agreement with
the estimated 1-10 ,uM Kd determined by NMR (8).
Adding 2 ,uM R24571 or 500,M diltiazem shifts the
titrations to the left of the control (no drug) curve (Fig. 1).
This indicates that R24571 and diltiazem can bind to
CDR and increase the apparent affinity of CDR for
felodipine by 15-fold with R24571 and fivefold with diltia-
zem. The inactive isomer of diltiazem, L-cis-diltiazem, and
verapamil are much less effective than diltiazem in produc-
ing these effects. These studies clearly indicate that the
CDR-ANT, R2457 1, and the Ca-ANT, diltiazem, can act
through an allosteric mechanism to increase the apparent
affinity of calmodulin for felodipine.
These allosteric interactions among drug-binding sites
on CDR may affect its mechanisms of action, because
these hydrophobic drug-binding sites also appear to be the
sites at which calmodulin binds the proteins it activates.
The degree of occupancy of these hydrophobic ligand-
binding sites on CDR by drugs, proteins, or by endogenous
regulators may determine the action and specificity of
CDR in regulating various Ca2+-dependent processes
within the cell.
Studies of 1,4 dihydropyridine binding to brain and
heart sarcolemmal membranes suggest that allosteric
interactions occur among Ca-ANT drug-binding sites on
Ca2+ channel proteins (4, 5). In fact, diltiazem (but neither
verapamil nor L-cis-diltiazem) potentiates dihydropyrid-
ine-binding to these membranes (5). We have shown
further that the CDR-ANT, R2457 1, can potentiate the
action of some Ca-ANT in altering Ca2+ currents (3).
These studies suggest that similar allosteric mechanisms
may exist among drug-binding sites on both the Ca2"
channel and on CDR.
At present it is difficult to say that CDR, itself, is the
Ca2" receptor of the Ca2" channel, because the affinity of
Ca-ANT for isolated, purified CDR is 10-1,000 times less
than their affinity for the Ca2" channel protein. Instead,
we propose that a Ca2"-binding protein, similar to CDR
but having a higher affinity for Ca-ANT drugs, is a Ca2"
receptor of the Ca2" channel and is a pharmacological
receptor for some Ca2"-antagonist drugs. In support of this
hypothesis we find that both our model Ca2"-binding
protein, CDR, and the Ca2"-channel protein(s) bind Ca2"
in the submicromolar range and act to facilitate their
regulatory functions; both bind and are inhibited by some
Ca-ANT and CDR-ANT drugs; and both exhibit allos-
teric interactions among their drug-binding sites.
The Ca2" channel is thought to be a multisubunit
protein (-200,000 M,) that traverses the cell membrane. It
presumably has Ca2'-binding sites on both its extracellular
side (Fig. 2, site 1) and its intracellular side (site 2).
Ca-ANT exert their effects at site 2 (9). The channel is
inactivated by a rise in [Ca2,]i and therefore by a Ca2,-
binding protein on its intracellular side. Our working
hypothesis suggests that site 2 is a calmodulin-like Ca2+
binding protein (CBP) which is the receptor for Ca-ANT
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FIGURE 2 A schematic representation of the possible role of a calmodu-
lin-like Ca2" binding protein (CBP) as a pharmacological receptor for
Ca2' antagonist drugs and as the Ca2+-dependent gate of the Ca2,
channel. The membrane is assumed to be depolarized.
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conditions of low [Ca2"]j, pCa > 7.0, the CBP gate (site 2)
is open and the channel can be opened in a voltage-
dependent manner. As [Ca2+]i rises (pCa < 7.0), Ca2+
binds to this CBP (site 2), closing or inactivating the
channel (Fig. 2 A).
Using CDR as a model for the CBP gate of the channel,
we recall that protein or drug binding to CDR is able to
increase its affinity for Ca2+ by nearly tenfold (10). Our
unpublished results show that R2457 1 binding to CDR can
increase the Ca2+ affinity of the Ca2+ sites that regulate
felodipine binding to CDR by as much as 50-fold.
If the CBP of site 2 is similar to CDR in this regard also,
then its binding of Ca-ANT could increase its affinity for
Ca2+ enough to bind Ca2 , close the channel, and keep it
closed even under low [Ca2+]i conditions (Fig. 3 B). Thus,
Ca-ANT may bind to the CBP gate of the channel,
potentiate Ca2+ binding to this protein, and thereby facili-
tate the action of [Ca2+]i in closing or inactivating the
channel. Under these circumstances, Ca2+ channel block-
ers are perhaps more Ca2+- agonists than Ca2+-antago-
nists, since they facilitate the action of intracellular Ca2+
with respect to channel blockade. Ca-ANT could vary in
the affinity and/or Ca2+ dependence of their binding to
this CBP gate and in their ability to increase its affinity for
Ca2+, which-might explain the differences in effectiveness
and frequency-dependence of various Ca-ANT's. Dif-
ferent Ca-ANT may have different allosterically-related
binding sites on this CBP, explaining the ability of some
drugs to potentiate the binding and action of other drugs.
Consistent with our hypothesis, we note that not all Ca2+
channels are inactivated by high [Ca2+]i. We would predict
that these channels do not have a CBP gate and would,
therefore, be insensitive to Ca-ANT drugs. It is well
documented, for example, that the Ca2+ channels regulat-
ing excitation-secretion are unique in that they are not
inactivated by high [Ca2+1] and are not sensitive to Ca-
ANT drugs. This could reflect their lack of a CBP that
gates the channel and binds Ca2+ channel blockers.
This hypothesis is particularly attractive because at least
two of its predictions are easily testable using current
methodologies. (a). We would predict that Ca-ANT can-
not block Ca2" currents in the presence of high concentra-
tions of intracellular Ca2" chelators (EGTA, EDTA). (b)
Ca-ANT binding to sarcolemma membrane preparations
rich in Ca2" channels should increase their affinity for
Ca2" in the same drug-dependent fashion as these drugs
block Ca2" influx. We submit this concept as a testable
hypothesis for further study.
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PROPERTIES OF A CATION CHANNEL OF LARGE UNIT
CONDUCTANCE IN LYMPHOCYTES, MACROPHAGES AND
CULTURED MUSCLE CELLS
H.-A. KOLB AND W. SCHWARZE
Faculty ofBiology, University ofKonstanz, D-7750 Konstanz, Federal Republic ofGermany
Using the patch-clamp method (1, 2), we have identified a experiments with nonexcitable cells, cultured FO-cells,
cation channel with novel properties in normal and trans- thymocytes, and peritonal macrophages of mouse were
formed nonexcitable cells as well as in excitable cells. For used.
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